A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma
1998

Study of Linomide and Interferon in Cancer Patients

Sample size: 31 publication Evidence: low

Author Information

Author(s): MJ Mackean, D Kerr, M Lesko, A Svedberg, F Hansson, D Jodrell, J Cassidy

Primary Institution: CRC Medical Oncology Department, Beatson Oncology Centre, Glasgow, UK

Hypothesis

Can Linomide combined with alpha interferon be tolerated and provide immunological benefits in patients with advanced malignant melanoma or renal carcinoma?

Conclusion

The combination of Linomide and alpha interferon does not support further exploration due to significant toxicity without the expected immunological benefits.

Supporting Evidence

  • The combination treatment was poorly tolerated, with 45% of patients stopping due to toxicity.
  • One patient achieved a complete response, while six had stable disease.
  • Significant toxicity included nausea, vomiting, and myalgia.

Takeaway

Doctors tested a new medicine called Linomide with another medicine called interferon to see if they could help people with serious skin and kidney cancers, but it made many people feel sick.

Methodology

Patients received Linomide for 2 weeks followed by alpha interferon, with monitoring of side effects and immune responses.

Potential Biases

Potential bias due to the single-center design and lack of a control group.

Limitations

The study had a small sample size and high dropout rate due to toxicity.

Participant Demographics

Median age was 54 years, with 21 men and 10 women; 24 had renal cell carcinoma and 7 had melanoma.

Statistical Information

P-Value

0.048

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication